ESMO 2024 – ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients
SHENZHEN, China, Sept. 15, 2024 /PRNewswire/ — ImmVira announced the latest clinical results for its lead oncolytic virus product, MVR-T3011, via intravesical administration in patients with high-risk BCG-failure non-muscle invasive bladder cancer (NMIBC). The results were published through po
Luohu Explores Economic Opportunities in Europe, Strengthens Ties with Portugal
LIBSON, Portugal, Sept. 15, 2024 /PRNewswire/ — In a strategic move following a recent tour of the Asia-Pacific region, the Luohu District in Shenzhen, located in South China’s Guangdong Province, has dispatched a new delegation to Spain and Portugal, with a focus on exploring economic
New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer
Investigational TAR-200 monotherapy demonstrates high complete response rate without the need for reinduction or additive therapy in patients who are Bacillus Calmette-Guérin (BCG)-unresponsive BARCELONA, Spain, Sept. 15, 2024 /PRNewswire/ — Johnson & Johnson (NYSE:JNJ) announced today
Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2024
Head-to-Head Phase 3 Trial Compared to Pembrolizumab Initiated HONG KONG, Sept. 15, 2024 /PRNewswire/ — At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso released the Phase 2 clinical results of its internally developed PD-1/VEGF bispecific antibody, ivonescimab, with
Akeso Published First-Ever Efficacy Data for PD-1/VEGF Bispecific Antibody Ivonescimab with or without CD47 Antibody plus FOLFOXIRI for mCRC at ESMO 2024
HONG KONG, Sept. 15, 2024 /PRNewswire/ — At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso (9926.HK) presented efficacy data for the first time for its internally developed PD-1/VEGF bispecific antibody, ivonescimab, with or without ligufalimab (anti-CD47 antibody AK1
KuCoin Cares Extends up to 10,000 KCS Humanitarian Aid to Typhoon Yagi Victims in Vietnam
VICTORIA, Seychelles, Sept. 15, 2024 /PRNewswire/ — In a prompt response to the devastating impact of Typhoon Yagi in Northern Vietnam, KuCoin is committed to airdropping up to 10,000 KCS to support the communities affected by the disaster. This donation is designed to provide immediate aid an
MSquare Technology Showcases Leadership in IP and Chiplet Innovation at the AI Hardware & Edge AI Summit
SAN JOSE, Calif., Sept. 15, 2024 /PRNewswire/ — From September 10-12, 2024, MSquare Technology made a standout appearance at the highly anticipated AI Hardware & Edge AI Summit in San Jose. With 1,500+ attendees and 75+ stellar speakers from the industry leaders, the summit provided MSqua
JOSH ROSS WINS BIG AT THE 2024 CCMA AWARDS PRESENTED BY TD
ROSS NAMED ENTERTAINER OF THE YEAR PRESENTED BY EDMONTON’S BEST HOTELS, MALE ARTIST OF THE YEAR, AND SECURES SINGLE OF THE YEAR WITH TROUBLE−MACKENZIE PORTER CROWNED FEMALE ARTIST OF THE YEAR−JAMES BARKER BAND TAKE HOME THE COVETED FANS’ CHOICE AWARD AND GROUP OR DUO OF THE YEAR−
CNOOC Limited Successfully Withstands Super Typhoon “Yagi”
HONG KONG, Sept. 14, 2024 /PRNewswire/ — CNOOC Limited (the “Company”, SEHK: 00883 (HKD Counter) and 80883 (RMB Counter), SSE: 600938) announces today that thanks to the Company’s continuous focus on safety and environmental protection performance, as well as its mature typho
Dialogue with CGT Leaders! You Are Invited to Join the “2024 GenScript Biotech Global Forum•London” to Discuss the Future Together
PISCATAWAY, N.J., Sept. 14, 2024 /PRNewswire/ — The year 2024 marks a milestone year for continuous advancements in Cell and Gene Therapy (CGT). The global launch of Amtagvi, a Tumor-Infiltrating Lymphocyte (TIL) therapy, has ushered in a new era for solid tumor treatment using cell therapy. P
